Delayed dominant-negative TNF gene therapy halts progressive loss of nigral dopaminergic neurons in a rat model of Parkinson's disease.
暂无分享,去创建一个
M. Tansey | A. Blesch | Armin Blesch | C. Barnum | Kelly A. Ruhn | Kelly A Ruhn | Ashley S Harms | Malú G Tansey | A. Harms | Christopher J Barnum | Steve Varghese | Isaac Treviño | Isaac Treviño | S. Varghese | K. Ruhn
[1] N. Greig,et al. TNF-alpha inhibition as a treatment strategy for neurodegenerative disorders: new drug candidates and targets. , 2007, Current Alzheimer research.
[2] D. German,et al. Midbrain dopaminergic neurons (nuclei A8, A9, and A10): Three‐dimensional reconstruction in the rat , 1993, The Journal of comparative neurology.
[3] M. Kaplitt. Parkinson disease: Another player in gene therapy for Parkinson disease , 2010, Nature Reviews Neurology.
[4] S. Mohand-Said,et al. Neurodegenerative and Neuroprotective Effects of Tumor Necrosis Factor (TNF) in Retinal Ischemia: Opposite Roles of TNF Receptor 1 and TNF Receptor 2 , 2002, The Journal of Neuroscience.
[5] W R Woodward,et al. Motor fluctuations in parkinson's disease , 1989, Annals of neurology.
[6] H. Gundersen,et al. Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator , 1991, The Anatomical record.
[7] I. Verma,et al. Transgenesis by lentiviral vectors: Lack of gene silencing in mammalian embryonic stem cells and preimplantation embryos , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[8] Eugene A Zhukovsky,et al. Inactivation of TNF Signaling by Rationally Designed Dominant-Negative TNF Variants , 2003, Science.
[9] M. Tuszynski,et al. Neurotrophin-3 Gradients Established by Lentiviral Gene Delivery Promote Short-Distance Axonal Bridging beyond Cellular Grafts in the Injured Spinal Cord , 2006, The Journal of Neuroscience.
[10] M. Goldberg,et al. Parkin Deficiency Increases Vulnerability to Inflammation-Related Nigral Degeneration , 2008, The Journal of Neuroscience.
[11] W. H. Oertel,et al. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: A combined retrograde tracing and immunocytochemical study in the rat , 1994, Neuroscience.
[12] Ole Isacson,et al. Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease , 2004, Journal of Neuroinflammation.
[13] T. Jones,et al. "Exuberant" Neuronal Growth After Brain Damage in Adult Rats: The Essential Role of Behavioral Experience , 1993, Journal of neural transplantation & plasticity.
[14] G. Opala,et al. Interleukin-10 (IL10) and tumor necrosis factor alpha (TNF) gene polymorphisms in Parkinson's disease patients. , 2008, Parkinsonism & related disorders.
[15] E. Hirsch,et al. Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease , 1994, Neuroscience Letters.
[16] B. Harvey,et al. Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS. , 2010, Pharmacological research.
[17] Terina N. Martinez,et al. Intranigral lentiviral delivery of dominant-negative TNF attenuates neurodegeneration and behavioral deficits in hemiparkinsonian rats. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.
[18] W. Robinson,et al. Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? , 2001, Arthritis and rheumatism.
[19] M. Kaplitt,et al. Gene therapy of the central nervous system : from bench to bedside , 2006 .
[20] A. Björklund,et al. Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by intrastriatal 6-hydroxydopamine in the rat , 1996, Neuroscience.
[21] Anders Björklund,et al. Characterization of Behavioral and Neurodegenerative Changes Following Partial Lesions of the Nigrostriatal Dopamine System Induced by Intrastriatal 6-Hydroxydopamine in the Rat , 1998, Experimental Neurology.
[22] M. Tansey,et al. Journal of Neuroinflammation BioMed Central Review , 2008 .
[23] F. LaFerla,et al. Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology , 2009, Neurobiology of Disease.
[24] Philippe Hantraye,et al. Dopamine Gene Therapy for Parkinson’s Disease in a Nonhuman Primate Without Associated Dyskinesia , 2009, Science Translational Medicine.
[25] P. Mcgeer,et al. Glial reactions in Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.
[26] C. Warren Olanow,et al. The scientific and clinical basis for the treatment of Parkinson disease (2009) , 2009, Neurology.
[27] J. Sinsheimer,et al. Inflammatory cytokine gene polymorphisms and increased risk of Parkinson disease. , 2007, Archives of neurology.
[28] J. Feldon,et al. Genetic ablation of tumor necrosis factor‐alpha (TNF‐α) and pharmacological inhibition of TNF‐synthesis attenuates MPTP toxicity in mouse striatum , 2004, Journal of neurochemistry.
[29] D. Miller,et al. Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: Implications for Parkinson's disease , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[30] M. Tansey,et al. Molecular Neurodegeneration BioMed Central Review , 2009 .
[31] J. Ting,et al. TNFα promotes proliferation of oligodendrocyte progenitors and remyelination , 2001, Nature Neuroscience.
[32] Reto Guler,et al. Contribution of transmembrane tumor necrosis factor to host defense against Mycobacterium bovis bacillus Calmette-guerin and Mycobacterium tuberculosis infections. , 2005, The American journal of pathology.
[33] B. Botterman,et al. Blocking Soluble Tumor Necrosis Factor Signaling with Dominant-Negative Tumor Necrosis Factor Inhibitor Attenuates Loss of Dopaminergic Neurons in Models of Parkinson's Disease , 2006, The Journal of Neuroscience.
[34] M. Mattson,et al. Tumor necrosis factors alpha and beta protect neurons against amyloid beta-peptide toxicity: evidence for involvement of a kappa B-binding factor and attenuation of peroxide and Ca2+ accumulation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[35] Minoru Harada,et al. Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients , 1994, Neuroscience Letters.
[36] R. Kaji,et al. Tumor necrosis factor gene polymorphisms in patients with sporadic Parkinson's disease , 2001, Neuroscience Letters.
[37] G. Kollias,et al. A tumor necrosis factor‐induced model of human primary demyelinating diseases develops in immunodeficient mice , 1999, European journal of immunology.
[38] F. LaFerla,et al. Chronic neuron-specific tumor necrosis factor-alpha expression enhances the local inflammatory environment ultimately leading to neuronal death in 3xTg-AD mice. , 2008, The American journal of pathology.
[39] T. Jones,et al. Testing forelimb placing “across the midline” reveals distinct, lesion-dependent patterns of recovery in rats , 2005, Experimental Neurology.
[40] O. Isacson,et al. Neuroinflammation mediated by IL-1β increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease , 2008, Journal of Neuroinflammation.
[41] F. Barkhof,et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2 , 1996, Neurology.
[42] G. Weissmann,et al. Science fraud: from patchwork mouse to patchwork data , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.